Skip to main content

News

ALN
May 21, 2020
Findings from a recent study showed tyrosine kinase inhibitors (TKIs) were associated with an increased risk for respiratory infections, but not serious pulmonary adverse events.
ALN
May 21, 2020
Results from a recent study show patients with rheumatoid arthritis have an approximately 20% increased risk for heart failure, independent of other risk factors.
The Dermatologist
May 21, 2020
Findings from a recent study indicated that several comorbidities precede a diagnosis of hidradenitis suppurativa, and that several develop afterwards.
ALN
May 21, 2020
A recent systematic review and meta-analysis assessed the association between the use of biologic agents and the risk for developing melanoma among patients with immune-mediated inflammatory diseases.
Rheumatology Consultant
May 20, 2020
Steven Romano, MD, executive vice president and chief scientific officer at Mallinckrodt, answers our questions about his team’s research on the effects of Acthar therapy on patients with rheumatoid arthritis.
Gastroenterology Consultant
May 20, 2020
In a new study, researchers sought to clarify how the gut microbe may influence chronic gastrointestinal disease. The coauthors Michael C. Hoaglin, MD and Melissa Agnello, PhD answered our questions about their research.
ALN
May 19, 2020
Researchers identified two novel inflammatory markers that show promise for assessing disease activity among patients with rheumatoid arthritis.
ALN
May 18, 2020
Findings from a recent study showed an IL-17 inhibitor was associated with complete or partial response among patients with a mucosal and articular phenotype of Behçet syndrome who were refractory to treatment with traditional therapies and tumor necrosis factor inhibitors.
The Dermatologist
May 18, 2020
Findings from an open label cohort study showed treatment of moderate to severe hidradenitis suppurativa with an IL-17 inhibitor was associated clinical response and had a favorable safety profile.
ALN
May 18, 2020
Experts from the United States, France, and Germany published guidance on managing patients with autoimmune bullous diseases during the COVID-19 pandemic.
Back to Top